Made for MASH.*

Rezdiffra works directly in the liver to reactivate liver cells, helping to reduce liver fat.

^*With moderate to advanced liver scarring without cirrhosis.

MASH was formerly called NASH (nonalcoholic steatohepatitis).

Real Patient

Could Rezdiffra make a difference for you?

Click where you are in your journey to get started.

I have MASH
with liver scarring.
What now?

I have fatty liver disease. Could it actually be MASH with liver scarring?

EVENTS

Register for free in-person events and virtual webinars.

Join in-person events and virtual webinars featuring discussions between Nurse Educators and Rezdiffra Real Voices™ Ambassadors. Ask questions and get helpful tips from other people living with MASH with moderate to advanced liver scarring without cirrhosis.

Explore events

Important Safety Information and Indication

Expand Collapse

Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

have any liver problems other than MASH.
have gallbladder problems or have been told you have gallbladder problems, including gallstones.
are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
- A pregnancy safety study for women who take Rezdiffra during pregnancy collects information about the health of you and your baby. You or your healthcare provider can report your pregnancy by visiting https://pregnancyregistry.madrigalpharma.com/ or calling 1-800-905-0324.
are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides because Rezdiffra is not recommended in patients taking these medicines.
Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of Rezdiffra?

Rezdiffra may cause serious side effects, including:

liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness.
gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.

These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1-800-905-0324.

What is Rezdiffra?

Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

Please see the full Prescribing Information, including Patient Information, for Rezdiffra.